A reduced density of α7-nAChR has been seen post-mortem in patients with Alzheimer's disease (AD) and schizophrenia.3 Therefore, α7-nAChR is assumed to be an important target to treat neurodegenerative and neuropsychiatric diseases. Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.